Login / Signup

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.

Taro IguchiSatoshi TamadaMinoru KatoSayaka YasudaTaiyo OtoshiKosuke HamadaTakeshi YamasakiTatsuya Nakatani
Published in: International journal of clinical oncology (2019)
AAT with subsequent flutamide after CAB therapy with bicalutamide may be suitable for some CRPC patients.
Keyphrases
  • end stage renal disease
  • prostate cancer
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • patient reported outcomes
  • bone marrow
  • smoking cessation